JP2020526582A - 体外受精の成功率を向上させるための膣ラクトバチルスの使用 - Google Patents

体外受精の成功率を向上させるための膣ラクトバチルスの使用 Download PDF

Info

Publication number
JP2020526582A
JP2020526582A JP2020521495A JP2020521495A JP2020526582A JP 2020526582 A JP2020526582 A JP 2020526582A JP 2020521495 A JP2020521495 A JP 2020521495A JP 2020521495 A JP2020521495 A JP 2020521495A JP 2020526582 A JP2020526582 A JP 2020526582A
Authority
JP
Japan
Prior art keywords
lactobacillus
administered
antibiotic
species
woman
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020521495A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020526582A5 (https=
Inventor
ピー． パークス、トーマス
ピー． パークス、トーマス
フメイダン、ピーター
スコフ イェンセン、ヨルゲン
スコフ イェンセン、ヨルゲン
ハー、トール
ウルドビャーグ、ニールズ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Statens Serum Institut SSI
Original Assignee
Statens Serum Institut SSI
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Statens Serum Institut SSI filed Critical Statens Serum Institut SSI
Publication of JP2020526582A publication Critical patent/JP2020526582A/ja
Publication of JP2020526582A5 publication Critical patent/JP2020526582A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/04—Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/36—Gynecology or obstetrics
    • G01N2800/367—Infertility, e.g. sperm disorder, ovulatory dysfunction

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gynecology & Obstetrics (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Endocrinology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pregnancy & Childbirth (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
JP2020521495A 2017-07-07 2018-07-05 体外受精の成功率を向上させるための膣ラクトバチルスの使用 Pending JP2020526582A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762529733P 2017-07-07 2017-07-07
US62/529,733 2017-07-07
PCT/US2018/040882 WO2019010281A1 (en) 2017-07-07 2018-07-05 USE OF VAGINAL LACTOBACILLES TO IMPROVE IN VITRO FERTILIZATION RATE OF SUCCESS

Publications (2)

Publication Number Publication Date
JP2020526582A true JP2020526582A (ja) 2020-08-31
JP2020526582A5 JP2020526582A5 (https=) 2021-07-29

Family

ID=64951221

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020521495A Pending JP2020526582A (ja) 2017-07-07 2018-07-05 体外受精の成功率を向上させるための膣ラクトバチルスの使用

Country Status (7)

Country Link
US (1) US11278581B2 (https=)
EP (1) EP3648779A4 (https=)
JP (1) JP2020526582A (https=)
CN (1) CN110831610A (https=)
AU (1) AU2018298116A1 (https=)
CA (1) CA3068974A1 (https=)
WO (1) WO2019010281A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3648779A4 (en) * 2017-07-07 2021-03-17 Osel, Inc. USING VAGINAL LACTOBACILLI TO IMPROVE THE SUCCESS RATE OF IN VITRO FERTILIZATION
EP4294417A1 (en) * 2021-02-19 2023-12-27 Imperial College Innovations Limited Lactobacillus crispatus composition for use in pregnant subjects
CN115181711B (zh) * 2022-09-14 2022-12-13 中国农业科学院北京畜牧兽医研究所 人乳杆菌lhm11及菌剂和应用
CN116804176B (zh) * 2023-06-14 2024-07-02 善恩康生物科技（苏州）有限公司 一株阴道卷曲乳酸杆菌及其在制备防治慢性子宫内膜炎和由ce引起的女性不孕症的药物中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999064023A1 (en) * 1998-06-05 1999-12-16 Wakamoto Pharmaceutical Co., Ltd. Lactic acid bacterium-containing compositions, drugs and foods
WO2015067141A1 (zh) * 2013-11-08 2015-05-14 苏州欧赛微科生物医药科技有限公司 一种卷曲乳杆菌及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6093394A (en) * 1997-04-11 2000-07-25 Gynelogix, Inc. Vaginal lactobacillus medicant
MX2009000053A (es) * 2006-07-12 2009-02-23 Controlled Therapeutics Sct Polimero para el suministro de medicamentos con sal clorhidrato de clindamicina.
US20110066137A1 (en) * 2007-12-18 2011-03-17 Osel, Inc. Applicator for applying powder formulations and uses thereof
US8329447B2 (en) * 2008-12-12 2012-12-11 Osel, Inc. Strain of Lactobacillus crispatus
CN103911306B (zh) * 2013-01-05 2016-08-24 欣力菲生物医药技术（天津）有限公司 加氏乳杆菌菌株及其用途
CN104178437B (zh) * 2013-11-08 2016-08-24 苏州欧赛微科生物医药科技有限公司 一种卷曲乳杆菌及其在妇科疾病中的应用
US10398742B2 (en) * 2014-12-15 2019-09-03 The Johns Hopkins University CVS transplantation for treatment of bacterial vaginosis
WO2018045359A1 (en) * 2016-09-02 2018-03-08 Karius, Inc. Detection and treatment of infection during pregnancy
EP3648779A4 (en) * 2017-07-07 2021-03-17 Osel, Inc. USING VAGINAL LACTOBACILLI TO IMPROVE THE SUCCESS RATE OF IN VITRO FERTILIZATION
WO2019010282A1 (en) * 2017-07-07 2019-01-10 Osel, Inc. STABILIZED FORMULATIONS WITH HIGH POWER OF LACTOBACILLUS VAGINAL
US10918663B2 (en) * 2018-04-03 2021-02-16 Reoxcyn, Llc Compositions and methods for the treatment of bacterial vaginosis
JP7445980B2 (ja) * 2018-05-22 2024-03-08 アートプレッド ビー． ブイ． 生殖補助医療手法の転帰の予測方法およびキット
WO2020007780A1 (en) * 2018-07-02 2020-01-09 Artpred B.V. Method and kit for altering the outcome of an assisted reproductive technology procedure
EP3843701B1 (en) * 2018-08-30 2024-02-21 Osel, Inc. Bacteriocins to improve vaginal colonization of hydrogen peroxide producing lactobacillus for female reproductive health

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999064023A1 (en) * 1998-06-05 1999-12-16 Wakamoto Pharmaceutical Co., Ltd. Lactic acid bacterium-containing compositions, drugs and foods
WO2015067141A1 (zh) * 2013-11-08 2015-05-14 苏州欧赛微科生物医药科技有限公司 一种卷曲乳杆菌及其应用

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CLINICAL TRIALS REGISTER. EUDRACT NUMBER;2016-002385-31, 2016, "A-DOUBLE-BLIND, PLACEBO-CONTROLLED M, JPN6022031857, ISSN: 0005044903 *
FRONT PHYSIOL., 2017 JUN 19, VOL.8 ARTICLE.415(P.1-6), JPN6022031856, ISSN: 0005044902 *
SEX TRANSM DIS., 2010, VOL.37 NO.12, P.745-750, JPN6022031859, ISSN: 0005044904 *

Also Published As

Publication number Publication date
CA3068974A1 (en) 2019-01-10
WO2019010281A1 (en) 2019-01-10
EP3648779A1 (en) 2020-05-13
US11278581B2 (en) 2022-03-22
EP3648779A4 (en) 2021-03-17
CN110831610A (zh) 2020-02-21
US20200164007A1 (en) 2020-05-28
AU2018298116A1 (en) 2020-02-27

Similar Documents

Publication Publication Date Title
TWI652343B (zh) 一種捲曲乳桿菌（ｌａｃｔｏｂａｃｉｌｌｕｓ ｃｒｉｓｐａｔｕｓ）及其應用
US12303538B2 (en) High potency stable formulations of vaginal lactobacillus
US20240156885A1 (en) Vaginal microbiota-associated methods, compositions, and devices
WO2022100633A1 (zh) 用于预防和/或治疗生殖道菌群紊乱相关疾病的格氏乳杆菌
US11278581B2 (en) Use of vaginal Lactobacilli for improving the success rate of in vitro fertilization
US20250345375A1 (en) Lactobacillus crispatus composition for use in pregnant subjects
US20250382676A1 (en) Methods of identifying strains associated with the human female genitourinary tract
WO2024052864A1 (en) Vaginal microbiota compositions for use in infertility
US20110135615A1 (en) Transiently buffered lactobacillus preparations and use thereof
CN110538201A (zh) 一种乳杆菌组合物及其用途
CA3068958C (en) High potency stable formulations of vaginal lactobacillus
CN117177761A (zh) 用于妊娠受试者的卷曲乳杆菌组合物
EP4658285A1 (en) Vaginal microbiota compositions for treating recurrent pregnancy loss
WO2025261345A1 (zh) 新型乳杆菌菌株及其组合物和应用
CN118542885A (zh) 一种乳酸菌二联活菌制剂、其制备方法及应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210621

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210621

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220802

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221028

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230202

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230425